| |AUGUST 20269USFDA CLEARS ALEMBIC PHARMA'S GENERIC CONSTIPATION TREATMENTHEALTHCARE COMPLIANCE OVERHAUL SET TO TRANSFORM SMALLER CITIESHYDERABAD GETS LIFELINE CENTRE FOR DIABETIC WOUND CAREWHY MARKETS ARE WATCHING ALEMBIC'S NEW USFDA APPROVALWHY TATA ELXSI-SCTIMST PARTNERSHIP MATTERS FOR INDIA'S MEDTECH GROWTHIndian drugmaker Alembic Pharma has expanded its US portfolio with USFDA approval for generic constipation treatment. The medicine is used to treat chronic idiopathic constipation in adults. The approval gives the company access to a market worth about USD 100 million.The approval covers 1 mg and 2 mg strengths. The medicine treats chronic idiopathic constipation in adults. This approval gives the company access to a market worth nearly USD 100 million in the United States. The approval came through the company's ANDA filed with the US regulator. The approved tablets are therapeutically equivalent to Takeda Pharmaceuticals USA's Motegrity tablets. POThe Centre's healthcare compliance overhaul could become a major boost for hospitals in smaller cities. The government plans to simplify regulations and reduce the burden of Hyderabad strengthens its healthcare landscape with a dedicated centre focused on diabetic wound care, advanced wound healing, and limb salvage. The newly launched facility marks a significant step in addressing complex, non-healing wounds linked to diabetes and vascular diseases.The centre brings together specialized expertise, modern treatment protocols, and multidisciplinary care to reduce amputation risks. With rising diabetes cases in India, the demand for focused diabetic wound care continues to grow. This initiative responds directly to that need by offering structured, evidence-based treatment pathways and improving patient outcomes through early intervention and specialized care delivery. POAlembic Pharmaceuticals has secured USFDA approval for its generic prucalopride tablets, drawing sharp market attention. This USFDA approval allows Alembic to expand its footprint in India's healthcare sector is set for a major technology push as the Tata Elxsi-SCTIMST Partnership brings together engineering expertise and medical research capabilities. The collaboration between Tata Elxsi and Sree Chitra Tirunal Institute for Medical Sciences and Technology (SCTIMST) aims to accelerate MedTech Growth.It will develop advanced healthcare solutions, medical devices, and digital health technologies. The partnership will combine SCTIMST's experience in biomedical research and clinical sciences with Tata Elxsi's strengths in product engineering, artificial intelligence, design, and digital technologies. The move is expected to support the development of innovative healthcare solutions for India and global markets. POthe United States, the world's largest pharmaceutical market. The approved drug treats chronic idiopathic constipation, a condition with steady prescription demand. Alembic now strengthens its generics pipeline and enhances revenue visibility through this approval.Investors and analysts track this development closely because every USFDA approval signals regulatory strength, market entry potential, and long-term growth opportunities. POmultiple inspections. The healthcare compliance reforms aim to improve ease of doing business.They also seek to attract more private investments in Tier-2 and Tier-3 cities. The move is expected to strengthen healthcare access while maintaining quality standards. The proposal comes as India faces rising demand for quality healthcare beyond metro cities. Many hospitals currently struggle with overlapping regulations. They also deal with repeated inspections from different agencies. PO
< Page 8 | Page 10 >